- CAR-T therapy can cure terminally ill cancer patients but it is prohibitively expensive, costing hundreds of thousands of dollars.
- Leveraging recent advances in chip technology scientists can create and mass produce small machines to re-engineer the immune system.
- But the scientific community needs public-private partnerships to ensure this medical breakthrough becomes accessible to everyone.
After suffering 16 months of chemotherapy for her leukaemia, treatment options for six-year-old Emily Whitehead had run out. Her parents began to fear the worst. As a last-ditch effort, the University of Pennsylvania enrolled Emily in a clinical trial that involved reprogramming her immune cells to destroy her cancer. The results were phenomenal. Emily not only survived, but nine years later she is a healthy teenager with no cancer.
Behind Emily’s recovery is CAR-T (Chimeric Antigen Receptor T cells ) a cell-based therapy that has become a revolutionary weapon in the treatment of previously incurable blood cancers.
CAR-T cell therapy genetically modifies a patient’s immune cells to hunt and kill cancer cells. It is a form of personalized immunotherapy that can provide lasting remissions, even to terminally ill patients who have just months to live and for whom classic treatment options have not worked.
More than 400 clinical trials of CAR-T therapies are currently in progress. Their impact could be enormous. According to the World Health Organization, cancer causes one in six deaths worldwide. Personalized cell therapy has the potential to save millions of lives. Preliminary data even suggests that engineering immune cells may one day be used to treat heart failure, autoimmune diseases, diabetes and HIV.
Why does CAR-T cost so much?
But unit economics are hobbling the rollout of CAR-T to the full number of patients whose lives it could save. The treatment alone can cost up to $475,000 and US hospitals can charge as much as $1.5 million to administer it, once ancillary costs are taken into account.
So why this high price? With conventional therapies, drug makers get economies of scale: the more they produce, the cheaper each dose becomes.
But CAR-T is tailor-made for each patient, and behind every treatment lies a highly sophisticated process, which is time-consuming and brutally expensive.
The patient’s immune cells are collected, purified in various steps, genetically modified, formulated at the right dose and reinfused. This complex manufacturing process requires shipments to different labs and frequent manual interventions, which introduce the risk of human error and potentially life-threatening side effects. Compounded by the fact that CAR-T consists of living cells that vary in potency, manufacturers need to continuously test results throughout the process.
The result is a production time that can take weeks, and an unaffordable price. Unless these economics change, this treatment will not reach patients whose lives it could save – it will only reach those privileged enough to afford it.
Technology holds the key to reducing costs
There is, however, hope. The most recent insights in nanotechnology, artificial intelligence (AI), biosensors, and the Internet of Things could help overcome the current roadblocks in making personalized cell therapies affordable.
The solution to democratize these therapies lies in automating their manufacturing process, which would reduce the cost, time, and risks significantly. This will require several engineering breakthroughs but is technically possible.
Recent advances in chip technology provide inspiration. The modern world’s insatiable demand for better computers, gaming consoles, and smartphones has resulted in the extreme miniaturization of transistors – the components which drive technology’s processing capacity – as more transistors on smaller circuits enables new and stronger technological abilities…..
When covid-19 struck Europe in March 2020, hospitals were plunged into a health crisis that was still badly understood. “Doctors really didn’t have a clue how to manage these patients,” says Laure Wynants, an [...]
Pfizer found to be 88 per cent effective at preventing symptomatic disease from delta variant. Two doses of Pfizer-BioNTech or AstraZeneca-Oxford's COVID-19 vaccines are nearly as effective against the highly transmissible delta coronavirus variant [...]
South African pharmaceutical company Aspen said Monday it was releasing its first batch of African-produced COVID-19 vaccines under a licensing deal with the US giant Johnson & Johnson. The Durban-based company said the first [...]
Since the coronavirus pandemic shut down the world, scientists have clamored to develop vaccines to prevent the spread and medicines that will cure the sick. But a virus’ main goal is to replicate and [...]
The highly transmissible delta variant of SARS-CoV-2, the coronavirus causing the disease COVID-19, is now present in 124 countries and will become the dominant strain globally in the coming months as it is outcompeting [...]
Scientists have backed proposals for Covid boosters in the autumn after blood tests on hundreds of people revealed that protective antibodies can wane substantially within weeks of second vaccine shots being given. Falls in [...]
Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall [...]
CSIRO, Australia's national science agency, played an important role in evaluating heat-tolerant COVID-19 vaccine formulations developed by the Indian Institute of Science (IISc) and biotech start-up Mynvax—against all current SARS-CoV-2 variants of concern. Published [...]
Podcast – Nanovisaging 2040 How Synergies between Nanotechnology, Nanomedicine, and AI might Benefit Humanity
Frank Boehm (NanoApps Medical Inc. Founder) in discussion with Nana Kay in a Wealth Secrets podcast. EP 19. Nanovisaging 2040. From Nana Kay: Nanovisaging 2040: How Synergies between Nanotechnology, Nanomedicine, and AI might Benefit [...]
Canada, like several other countries, has been mixing and matching COVID-19 vaccines for weeks amid safety concerns over the AstraZeneca shot. On Monday, the chief scientist at the World Health Organization (WHO) cautioned against that approach, calling [...]
Scientists have harnessed CRISPR gene-editing technology to block the replication of the novel coronavirus in human cells — an approach that could one day serve as a new treatment for COVID-19. However, the study was performed [...]
A recent study by scientists from Japanese universities has shown that the shape of cell-derived nanoparticles, known as "extracellular vesicles" (EVs), in body fluids could be a biomarker for identifying types of cancer. In [...]
An important lesson for vaccine design Australian scientists researching how our immune system responds to COVID-19 have revealed that those infected by early variants in 2020 produced sustained antibodies, however, these antibodies are not [...]
1. How COVID-19 is affecting the globe Confirmed cases of COVID-19 have passed 185 million globally, according to Johns Hopkins University. The number of confirmed deaths stands at more than 4 million. More than 3.29 [...]
The World Health Organization (WHO) has added another COVID strain to its list of coronavirus variants to keep an eye on: the COVID-19 Lambda variant. This particular variant has now spread to more than two dozen [...]